|
Revolutionizing cancer therapy: a scoping review of organoid based personalized immunotherapy
|
Sahand Hedayati-Omami1    , Negin Alidoost Zoghi2 , Seyedeh Saba Mirian2 |
1- School of Medicine, TMS, Islamic Azad University, Tehran, Iran , sahand.hedayati2@gmail.com
2- Student Research Committee, School of Pharmacy, TMS, Islamic Azad University, Tehran, Iran |
|
|
Abstract: (7 Views) |
Abstract
Background: Immunotherapy, an approach using the immune system to combat Cancers, has faced challenges with traditional models that do not fully represent the tumor's immune microenvironment (TIME). The limitations of conventional cancer drug testing on 2D cultures are being addressed by modern techniques that enable the growth of biopsy-derived cancer cells in 3D structures. More representative models, like patient-derived organoids (PDOs), fill this gap. These organoids can mimic the tumor environment, aiding in developing personalized immunotherapy strategies. This scoping review aimed to comprehensively assess the potential of PDOs in developing and personalizing cancer immunotherapy.
Materials and methods: Data were extracted from relevant articles by searching databases. Search terms included "Organoid", "patient-derived organoid", "cancer" and "immunotherapy".
Results: Based on the reviewed articles, PDOs facilitate research in adoptive cellular therapy, including the use of tumor-infiltrating lymphocytes, natural killer cells, and chimeric antigen receptor-T cell therapies. Organoids are presently employed as investigative instruments to assess the efficacy of diverse immunotherapeutic strategies. This utilization could aid in uncovering immune evasion mechanisms and elucidate the intricate intercommunication between tumor cells and immune cells, providing a deeper understanding of cancer immunotherapy.
Conclusion: PDOs accurately replicate tumor characteristics, including histology, genetic diversity, and microenvironments, which are vital for predicting immunotherapy efficacy in patients. They enhance the evaluation of treatment strategies, allowing scientists to test various immunotherapy agents and identify the best therapy for a specific tumor.
|
|
| Keywords: Patient-derived organoids (PDOs), Cancer, Organoid, Immunotherapy |
|
|
Full-Text [PDF 666 kb]
(2 Downloads)
|
Semi-pilot: Review |
Subject:
Pharmacology
Received: 2024/10/12 | Accepted: 2025/02/16 | Published: 2025/12/1
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
